Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haider Mahdi

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|April 19, 2011
Disparities in treatment and survival between African American and White women with vaginal cancerHaider Mahdi, Sanjeev Kumar, Rabbie K Hanna, et al.
Gynecologic Oncology|December 17, 2014
Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution studyMohamed A Elshaikh, Zaid Al-Wahab, Haider Mahdi, et al.
Gynecologic Oncology|January 11, 2015
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional studyHaider Mahdi, Peter G Rose, Mohammed A Elshaikh, et al.
Gynecologic Oncology|February 3, 2015
Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution studyHaider Mahdi, Mohamed A Elshaikh, Robert DeBenardo, et al.
Oncoimmunology|April 17, 2023
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppressionPaul G Pavicic, Patricia A Rayman, Shadi Swaidani, et al.
JNCI Cancer Spectrum|June 30, 2020
Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort StudyStefan Klek, Brandie Heald, Alex Milinovich, et al.
Communications Medicine|January 3, 2024
Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignanciesArpit Aggarwal, Sirvan Khalighi, Deepak Babu, et al.
American Journal of Epidemiology|January 18, 2025
Adjuvant Therapy in Early Uterine Serous CarcinomaAlison A Garrett, Taylor H Orellana, T Rinda Soong, et al.
Gynecologic Oncology|November 4, 2022
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinomaSarah A Ackroyd, David Arguello, Pilar Ramos, et al.
NPJ Precision Oncology|July 19, 2023
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibitionHussein Al-Sudani, Ying Ni, Philip Jones, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|April 19, 2011
Disparities in treatment and survival between African American and White women with vaginal cancerHaider Mahdi, Sanjeev Kumar, Rabbie K Hanna, et al.
Gynecologic Oncology|December 17, 2014
Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution studyMohamed A Elshaikh, Zaid Al-Wahab, Haider Mahdi, et al.
Gynecologic Oncology|January 11, 2015
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional studyHaider Mahdi, Peter G Rose, Mohammed A Elshaikh, et al.
Gynecologic Oncology|February 3, 2015
Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution studyHaider Mahdi, Mohamed A Elshaikh, Robert DeBenardo, et al.
Oncoimmunology|April 17, 2023
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppressionPaul G Pavicic, Patricia A Rayman, Shadi Swaidani, et al.
JNCI Cancer Spectrum|June 30, 2020
Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort StudyStefan Klek, Brandie Heald, Alex Milinovich, et al.
Communications Medicine|January 3, 2024
Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignanciesArpit Aggarwal, Sirvan Khalighi, Deepak Babu, et al.
American Journal of Epidemiology|January 18, 2025
Adjuvant Therapy in Early Uterine Serous CarcinomaAlison A Garrett, Taylor H Orellana, T Rinda Soong, et al.
Gynecologic Oncology|November 4, 2022
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinomaSarah A Ackroyd, David Arguello, Pilar Ramos, et al.
NPJ Precision Oncology|July 19, 2023
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibitionHussein Al-Sudani, Ying Ni, Philip Jones, et al.
Pageof 9